Viatris, Inc. (VTRS)
16.54
+0.22
(+1.38%)
USD |
NASDAQ |
Aug 24, 16:00
16.54
0.00 (0.00%)
After-Hours: 20:00
Viatris Enterprise Value : 31.07B for Aug. 21, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 21, 2026 | 31.07B |
| August 20, 2026 | 30.84B |
| August 19, 2026 | 30.98B |
| August 18, 2026 | 30.90B |
| August 17, 2026 | 30.97B |
| August 14, 2026 | 30.97B |
| August 13, 2026 | 30.75B |
| August 12, 2026 | 30.82B |
| August 11, 2026 | 31.02B |
| August 10, 2026 | 31.02B |
| August 07, 2026 | 31.20B |
| August 06, 2026 | 31.04B |
| August 05, 2026 | 32.61B |
| August 04, 2026 | 32.66B |
| August 03, 2026 | 32.58B |
| July 31, 2026 | 32.50B |
| July 30, 2026 | 32.73B |
| July 29, 2026 | 32.80B |
| July 28, 2026 | 32.85B |
| July 27, 2026 | 32.59B |
| July 24, 2026 | 32.13B |
| July 23, 2026 | 32.18B |
| July 22, 2026 | 31.87B |
| July 21, 2026 | 32.54B |
| July 20, 2026 | 31.84B |
| Date | Value |
|---|---|
| July 17, 2026 | 32.19B |
| July 16, 2026 | 32.24B |
| July 15, 2026 | 31.49B |
| July 14, 2026 | 31.06B |
| July 13, 2026 | 31.15B |
| July 10, 2026 | 31.01B |
| July 09, 2026 | 31.09B |
| July 08, 2026 | 31.46B |
| July 07, 2026 | 31.81B |
| July 06, 2026 | 31.62B |
| July 02, 2026 | 31.51B |
| July 01, 2026 | 30.91B |
| June 30, 2026 | 30.56B |
| June 29, 2026 | 31.25B |
| June 26, 2026 | 31.37B |
| June 25, 2026 | 31.06B |
| June 24, 2026 | 30.90B |
| June 23, 2026 | 30.69B |
| June 22, 2026 | 30.26B |
| June 18, 2026 | 30.25B |
| June 17, 2026 | 30.67B |
| June 16, 2026 | 31.03B |
| June 15, 2026 | 31.36B |
| June 12, 2026 | 31.54B |
| June 11, 2026 | 31.34B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Pfizer Inc. | 211.77B |
| Eli Lilly & Co. | 1.228T |
| Merck & Co., Inc. | 423.37B |
| Bristol Myers Squibb Co. | 170.89B |
| Johnson & Johnson | 679.08B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -118.80M |
| Revenue (Quarterly) | 3.762B |
| Total Expenses (Quarterly) | 3.881B |
| EPS Diluted (Quarterly) | -0.1021 |
| Gross Profit Margin (Quarterly) | 41.92% |
| Profit Margin (Quarterly) | -3.16% |
| Earnings Yield | -2.16% |
| Operating Earnings Yield | 7.42% |
| Normalized Earnings Yield | 3.050 |